KNSA

93.7400.22%
RM

Ross Michael Moat

President, Executive VP, COO & Principal Operating Officer

Mr. Ross Michael Moat has been the President at Kiniksa Pharmaceuticals International, plc since October 17, 2026. He is Chief Operating Officer and principal operating officer at Kiniksa Pharmaceuticals International, plc since January 10, 2026 and serves as its Executive Vice President since January 2026. He was Chief Corporate Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) from 2025 until January 10, 2026 and served as its Chief Commercial Officer since January 2022 until January 10, 2026 and Executive Vice President from January 2025 until January 10, 2026 and served as its Senior Vice President since January 2022 until December 2024. He is responsible for leading the Company’s sales, marketing and commercial operations across its portfolio, including the commercial launch of ARCALYST (rilonacept) in recurrent pericarditis. Prior to that, he served as Group Vice President and ARCALYST General Manager from February 2021 to January 2022, Vice President of European Operations and Rilonacept Franchise Commercial Head from July 2020 to February 2021 and as Vice President of European Operations from June 2019 to July 2020. Before joining Kiniksa, he served as Vice President of EMEA Marketing and Commercial Operations from May 2018 to June 2019 at AveXis, Inc., a Novartis AG company, where he led launch readiness planning and execution. Prior to that, he served as Executive Director of EU Genetic Diagnostic Strategy from July 2017 to February 2018 at Spark Therapeutics, Inc. ("Spark"), where he built a pre-launch field-facing team in sequential launch markets. Before joining Spark, he served as Senior Director, Commercial & Marketing Lead, EMEA from August 2015 to June 2017 at Alexion, where he developed the EMEA strategic and operational commercial plans for the metabolic business unit. Prior to that, he held various roles with increasing responsibilities at Synageva and ProStrakan Inc. He received his first-class BA (Honors) degree in Business Management from Middlesex University Business School in London.

Positions